How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

4,231 results for

Tongue Carcinoma

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

4001. Neoplastic transformation of oral lichen: case report and review of the literature Full Text available with Trip Pro

Neoplastic transformation of oral lichen: case report and review of the literature Aim of the present investigation was to analyse the possible malignant transformation of oral lichen planus to carcinoma, especially in the atrophic erosive forms and those displaying plaques involving the top of the tongue. A review has been made of the literature, from 1986 to the present day. This search outlines the relationship between oral lichen planus, hepatitis C virus infection, Epstein-Barr virus (...) infection and the importance of periodic follow-up in all patients with oral lichen planus. The case is described of malignant transformation of oral lichen planus to oral cancer in a female presenting asymptomatic hepatitis C virus infection. The clinical history confirms the most important aspects of the relationship between oral lichen planus and oral cancer. Oral lichen planus should be considered as a precancerous lesion, particularly in patients presenting hepatitis C virus infection, requiring

2006 Acta Otorhinolaryngologica Italica

4002. Cetuximab & Concomitant-Boost Accelerated RT in Patients With Locally Advanced Oropharynx Squamous Cell Carcinoma.

radiotherapy Additional relevant MeSH terms: Layout table for MeSH terms Carcinoma, Squamous Cell Oropharyngeal Neoplasms Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Neoplasms, Squamous Cell Pharyngeal Neoplasms Otorhinolaryngologic Neoplasms Head and Neck Neoplasms Neoplasms by Site Pharyngeal Diseases Stomatognathic Diseases Otorhinolaryngologic Diseases Cetuximab Antineoplastic Agents, Immunological Antineoplastic Agents (...) /treatment Phase Oropharyngeal Neoplasms Drug: Cetuximab Phase 2 Detailed Description: To determine the 1-year rate of locoregional disease control in the experimental arm, using a control arm to avoid selection bias. To determine the 2 and 3 year rate of locoregional disease control. To evaluate the safety and toxicity of the combination of cetuximab and concomitant-boost accelerated radiotherapy followed by 12 weeks of complementary treatment with cetuximab. Both acute and chronic toxicity

2005 Clinical Trials

4003. Fractionated Radiation Therapy in Treating Advanced Squamous Cell Carcinoma of the Head and Neck

: No Criteria DISEASE CHARACTERISTICS: Histologically proven squamous cell carcinoma of the head and neck, including lymphoepithelioma and anaplastic carcinoma Biopsy from the primary or regional nodes acceptable No adenocarcinomas The following stages and sites are eligible: Stage III/IV oral cavity, including: Anterior 2/3 of the tongue Buccal mucosa Floor of mouth Hard palate Gingiva Retromolar trigone Stage III/IV oropharynx, including: Tonsil and pillars Faucial arch and soft palate Posterolateral (...) pharyngeal walls Stage II/III/IV base of the tongue and hypopharynx Stage III/IV supraglottic larynx, including: Ventricular band Arytenoid Supra- and infrahyoid epiglottis Aryepiglottic fold (tumors at glottic and subglottic sites excluded) Nonpalpable nodes detected only on CT or MRI must be at least 1.0 cm in diameter or contain necrosis to prove N+ disease No metastasis below the clavicle clinically or radiologically PATIENT CHARACTERISTICS: Age: At least 18 Performance status: Karnofsky 60-100

2008 Clinical Trials

4004. Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Squamous Cell Carcinoma of Head and Neck Nasopharyngeal Carcinoma Paranasal Sinus Neoplasms Tongue Neoplasms Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Neoplasms, Squamous Cell Respiratory Tract Diseases Otorhinolaryngologic Diseases Otorhinolaryngologic Neoplasms Head and Neck Neoplasms Neoplasms by Site Respiratory Tract Neoplasms Pharyngeal Neoplasms Pharyngeal Diseases Stomatognathic Diseases Nasopharyngeal Neoplasms Nasopharyngeal Diseases Nose Neoplasms Nose (...) in treating head and neck cancer. Condition or disease Intervention/treatment Phase Recurrent Squamous Cell Carcinoma of the Hypopharynx Recurrent Squamous Cell Carcinoma of the Larynx Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity Recurrent Squamous Cell Carcinoma of the Nasopharynx Recurrent Squamous Cell Carcinoma of the Oropharynx Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity Recurrent Verrucous Carcinoma of the Larynx Recurrent Verrucous Carcinoma of the Oral

2005 Clinical Trials

4005. Patient Selection for Hypoxia Modifying Treatments in Larynx Carcinomas

radiotherapy combined with carbogen breathing and nicotinamide). Condition or disease Larynx Cancer Study Design Go to Layout table for study information Study Type : Observational Actual Enrollment : 79 participants Observational Model: Cohort Time Perspective: Prospective Official Title: Patient Selection for Hypoxia Modifying Treatments Based on Functional Microregional Imaging of Tumor Vasculature, Oxygenation and Proliferation in Squamous Cell Carcinoma of the Larynx Study Start Date : July 2001 (...) -classification (UICC 1997, appendix I): T3-4 glottic or supraglottic carcinoma T2 glottic carcinoma with impaired cord mobility or subglottic extension T2 supraglottic carcinoma with invasion of mucosa of base of tongue or vallecula or invasion of the medial wall of the piriform sinus. any N-stage, M0. WHO performance status 0 or 1. Age > 18 years. Written informed consent. Treatment in the ARCON phase III trial Exclusion Criteria: Prior or concurrent treatment for this tumour. Severe stridor and adequate

2005 Clinical Trials

4006. Phase II Study of Concurrent C225, Cisplatin and Radiation in Stage IV Squamous Cell Carcinoma of the Head and Neck

factor receptor pathway Prior chimerized or murine monoclonal antibody Active systemic infection Known allergy to murine proteins Severe chronic obstructive pulmonary disease requiring ≥ 3 hospitalizations within the past year Myocardial infarction within the past 3 months Uncontrolled congestive heart failure Unstable or uncontrolled angina Clinically apparent jaundice Postoperative recurrence Other malignancy within the past 3 years except resected basal cell or squamous cell skin cancer, carcinoma (...) with locally advanced or regional stage IV head and neck cancer that cannot be removed by surgery. Condition or disease Intervention/treatment Phase Head and Neck Cancer Biological: cetuximab C225 Drug: cisplatin Radiation: radiation therapy Phase 2 Detailed Description: OBJECTIVES: Primary Determine 2-year progression-free survival in patients with unresectable locally advanced or regional stage IV squamous cell or undifferentiated carcinoma of the head and neck treated with cetuximab, cisplatin

2004 Clinical Trials

4007. Docetaxel, Cisplatin (TP) + Radiation +/- Cetuximab in Larynx Carcinoma (CA)

containing rod), abstinence or sterilization (vasectomy) of the male) Exclusion Criteria: primary cancer treatable by operational larynx -conserving procedures distant metastases (M1-Status) total tumor volume exceeding 80 ml or larynx skeleton punctuated with infiltration of surrounding soft tissues respectively the esophageal aditus (exclusive cartilage infiltration represents no exclusion criteria) tumor-specific prior chemo or radiotherapy metachronous or synchronous malignant tumor (exception (...) . Dietz, Universität Leipzig, University of Leipzig ClinicalTrials.gov Identifier: Other Study ID Numbers: TP(F)+Radiation+/-Cetuximab First Posted: July 30, 2007 Last Update Posted: June 2, 2015 Last Verified: June 2015 Keywords provided by ClinAssess, University of Leipzig: by laryngectomy operable carcinoma of the larynx and the hypopharynx Additional relevant MeSH terms: Layout table for MeSH terms Carcinoma Carcinoma, Squamous Cell Laryngeal Diseases Laryngeal Neoplasms Neoplasms, Glandular

2007 Clinical Trials

4008. Discontinuous vs. in-continuity neck dissection in carcinoma of the oral cavity. Experience of two oncologic hospitals. Full Text available with Trip Pro

Discontinuous vs. in-continuity neck dissection in carcinoma of the oral cavity. Experience of two oncologic hospitals. Many Authors have discussed the best indication and extension of neck dissection, but few have studied the surgical approach considering the continuity of neck dissection with the primary tumour. This retrospective study refers to patients submitted to major surgery between 1996 and 2001 for floor of mouth and oral tongue squamous cell carcinoma, at the Head and Neck Surgery (...) Department of the Hospital "A.C. Camargo", São Paulo, Brazil and of the European Institute of Oncology, Milan, Italy. Patients were assigned to one of three groups: group I (in-continuity resection); group 2 (discontinuous resection) and group 3 (delayed discontinuous resection). Overall, 193 patients were studied. There were no differences in disease-free survival between the neck dissection groups. Furthermore, no statistical differences were found in disease specific survival between the groups

2007 Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale

4009. Post-Operative Adjuvant Concurrent Chemoradiotherapy For High Risk Oral Cavity Squamous Cell Carcinoma Patients

of this study is to confirm the value of concurrent chemoradiotherapy in improving the locoregional control and survival of patients with resected locally advanced HNSCC, a phase III randomized study is proposed. The population studied in this trial is limited to patients of oral cavity cancer; this could reduce the confounding factor of varying prognosis in patients of different primary sites of HNSCC. Condition or disease Intervention/treatment Phase Oral Cavity Squamous Cell Carcinoma Drug: cisplatin (...) Phase 3 Detailed Description: Potentially resectable Stage III or IV squamous cell carcinomas of the head and neck (HNSCC) are treated by operation and adjuvant radiotherapy. The 5-year survival rate is approximating 30%. Recurrence typically occurs within 3 years, 60-80% in locoregional sites, and 20-30% systemically. Patients who are found to have tumors at the margins of surgical specimens far particularly poorly. Chemotherapy has been added in the hope to improve this situation. Induction

2005 Clinical Trials

4010. Chemoprevention Study of Oral Cavity Squamous Cell Carcinoma

malignancy in the oral cavity cancer patients after curative local treatment and to study the toxicity and compliance of 13-cis retinoic acid. Condition or disease Intervention/treatment Phase Oral Cavity Squamous Cell Carcinoma Drug: 13-cis Retino Acid Phase 3 Detailed Description: There are more than one thousand deaths annually from head and neck cancer in Taiwan (excluding nasopharyngeal carcinoma) and the majority of treatment failures are related to recurrence of primary disease. Only patients (...) with early-stage disease have high cure rates, but they remain at risk for the development of second primary tumors. Second primary malignancies occur at a constant annual rate of 5% to 7% in all head and neck cancer patients1. Furthermore, because the mortality from primary disease recurrence plateaus after 2 to 3 years in patients with locally advanced disease, second primary tumors become the major cause of late cancer mortality. Sporn et al defined chemoprevention as an effort to arrest or reverse

2005 Clinical Trials

4011. Medpulser Electroporation With Bleomycin Study to Treat Posterior Head and Neck Squamous Cell Carcinoma

) of the base of the tongue, posterior lateral pharyngeal wall, hypopharynx or larynx. Condition or disease Intervention/treatment Phase Head Neck Cancer Combination Product: Medpulser Electroporation with Bleomycin Procedure: Surgical Excision Phase 3 Detailed Description: Recurrent tumors in head and neck squamous cell carcinoma usually have a poor prognosis. In patients suitable for salvage surgery of their recurrent disease, the success rate for local control has been reported to be 40-50%. The surgical (...) : October 15, 2018 Last Verified: October 2018 Keywords provided by Inovio Pharmaceuticals: Squamous Cell Carcinoma carcinoma head and neck cancer larynx electroporation medpulser bleomycin cancer Locally recurrent or second primary squamous cell carcinoma of the base of the tongue, posterior lateral pharyngeal wall, hypopharynx, or larynx Additional relevant MeSH terms: Layout table for MeSH terms Carcinoma Carcinoma, Squamous Cell Head and Neck Neoplasms Squamous Cell Carcinoma of Head and Neck

2005 Clinical Trials

4012. Elective vs Therapeutic Neck Dissection in Treatment of Early Node Negative Squamous Carcinoma of Oral Cavity

, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Histologically proven T1 or T2 N0 M0 (clinical) squamous cell carcinoma of the buccal mucosa, lower alveolus, oral tongue and floor of mouth. Surgery is the preferred treatment and the primary tumor can be excised with clear margins via the per-oral route. No history of a prior malignancy in the head and neck region. No prior malignancy outside the head and neck region in the preceding 5 years (...) . Patient will be reliable for follow-up Age> 18 years and < 75 years. No significant co-morbid conditions - ASA grade II and I. Understands the protocol and is able to give informed consent. Exclusion Criteria: Prior radiotherapy or surgery for malignancy in the head and neck region. Non squamous cell carcinomas of the oral cavity. Upper alveolus and palatal lesions where there is a possibility of retropharyngeal node involvement. Per-oral excision of tumor will compromise margins in the opinion

2005 Clinical Trials

4013. Identification of genes associated with cisplatin resistance in human oral squamous cell carcinoma cell line Full Text available with Trip Pro

a cisplatin-sensitive cell line, Tca8113, which was derived from moderately-differentiated tongue squamous cell carcinoma. Global gene expression in this resistant cell line and its sensitive parent cell line was analyzed using Affymetrix HG-U95Av2 microarrays. Candidate genes involved in DNA repair, the MAP pathway and cell cycle regulation were chosen to validate the microarray analysis results. Cell cycle distribution and apoptosis following cisplatin exposure were also investigated.Cisplatin (...) Identification of genes associated with cisplatin resistance in human oral squamous cell carcinoma cell line Cisplatin is widely used for chemotherapy of head and neck squamous cell carcinoma. However, details of the molecular mechanism responsible for cisplatin resistance are still unclear. The aim of this study was to identify the expression of genes related to cisplatin resistance in oral squamous cell carcinoma cells.A cisplatin-resistant cell line, Tca/cisplatin, was established from

2006 BMC cancer

4014. Thyroid papillary carcinoma arising in ectopic thyroid tissue within a neck branchial cyst Full Text available with Trip Pro

Thyroid papillary carcinoma arising in ectopic thyroid tissue within a neck branchial cyst Thyroid gland derives from one median anlage at the base of the tongue, and from the two fourth branchial pouches. A number of anomalies may occur during their migration. These can be in form of ectopic tissues, which are frequently found along the course of thyroglossal duct and rarely in other sites, many of these may develop same diseases as the thyroid gland.A 36-years-old female presented with a 3 (...) month history of left side neck mass. The mass disappeared following aspiration of brown colored fluid, which on cytological examination showed cells with nuclear irregularities that warranted the resection of the lesion. The histology demonstrated a thyroid papillary carcinoma arising within the branchial cyst. Thereafter, the patient underwent a total thyroidectomy with central lymph nodes dissection. Histology showed a multifocal papillary carcinoma with central lymph nodes metastases. Only four

2006 World journal of surgical oncology

4015. Topoisomerase II trapping agent teniposide induces apoptosis and G2/M or S phase arrest of oral squamous cell carcinoma Full Text available with Trip Pro

Topoisomerase II trapping agent teniposide induces apoptosis and G2/M or S phase arrest of oral squamous cell carcinoma Teniposide (VM-26) has been widely used in the treatment of small cell lung cancer, malignant lymphoma, breast cancer, etc. However, there are few reports on VM-26 against oral cancers. The present study was designed to identify the effect of VM-26 against oral squamous cell carcinoma in vitro, and to provide evidence for the feasibility and effectiveness of VM-26 (...) for application to the patients with oral cancer.Human tongue squamous cell carcinoma cell line, Tca8113, was used. Cells were incubated with different concentrations of VM-26 for a variety of time span. Cisplatin (CDDP) was employed as a control reagent. MTT assay was used to assess the inhibitory rate of Tca8113 growth. Flow cytometer (FCM), transmission electronic microscope (TEM) and fluorescence staining were employed for determining the cell apoptotic rate. Cell cycle distribution of Tca8113 incubated

2006 World journal of surgical oncology

4016. Oral squamous cell carcinoma: an atypical presentation mimicking temporomandibular joint disorder Full Text available with Trip Pro

Oral squamous cell carcinoma: an atypical presentation mimicking temporomandibular joint disorder A 50-year-old female presented to a chiropractic clinic with left jaw pain consistent with temporomandibular joint disorder. Examination revealed a large ulcerated mass on the posterolateral margin of the tongue which was later diagnosed as squamous cell carcinoma. Squamous cell carcinoma is the most common of the oral cancers. These cancers are often detected late making treatment more complicated (...) and reducing the chance of survival. In the early stages squamous cell carcinoma can be asymptomatic. Symptoms can be similar to that of temporomandibular joint disorder making examination of the patient's mouth important to rule out oral cancers. Oral cancers should be considered when patients present to a chiropractor with pain in the area of the temporomandibular joint. Risk factors such as chronic tobacco and alcohol use should raise concern in these patients. Suspicious lesions should be referred

2004 The Journal of the Canadian Chiropractic Association

4017. [Sparing normal oral tissues with individual dental stent in radiotherapy for primary nasopharyngeal carcinoma patients]. (Abstract)

[Sparing normal oral tissues with individual dental stent in radiotherapy for primary nasopharyngeal carcinoma patients]. With the progression of radiotherapy techniques, the 5-year overall survival rate of nasopharyngeal carcinoma (NPC) patients has increased obviously. As the survival time prolonged, more and more attention was paid to various radiation sequelae and the quality of life of the patients. This study was to explore the role of individual dental stent in sparing normal oral (...) tissues for primary NPC patients in radiotherapy by pushing the tongue and a part of oral mucous membrane away from the radiation fields.Irradiation dose and volume of the tongue of a NPC patient before and after wearing dental stent was evaluated. A total of 43 patients were randomized into 2 groups: 19 in trial group and 24 in control group. Trial group wore dental stent during radiotherapy, while control group did not. Patients' weight, taste, oral mucous reaction, and tongue mucous reaction before

2007 Ai zheng = Aizheng = Chinese journal of cancer Controlled trial quality: uncertain

4018. Effect of induction chemotherapy on changes of laminin and syndecan expression in oral squamous cell carcinomas: a prospective, randomized, clinicopathologic and immunohistochemical study. (Abstract)

Effect of induction chemotherapy on changes of laminin and syndecan expression in oral squamous cell carcinomas: a prospective, randomized, clinicopathologic and immunohistochemical study. Sixty patients with tumors of the floor of the mouth or of the tongue (T2N0-1-2M0) were randomized into three treatment groups. The first two groups participated in low-dose inductive chemotherapy, surgery, and then radiotherapy, whereas the third control group underwent only surgery and radiotherapy. In all (...) three groups, studies were made of the stage, grade, sex, localization, extents of expression of the pretreatment laminin and syndecan-1 and the cancer specific survival rate, and the correlations among these. The response to neoadjuvant chemotherapy was assessed by means of a method that we developed, involving measurement of the degree of histologic regression observed in response to chemotherapy. Immunohistochemical methods were applied to investigate the changes in degree of expression

2005 The Journal of craniofacial surgery Controlled trial quality: uncertain

4019. Expression of vascular endothelial growth factor-C does not predict occult lymph-node metastasis in early oral squamous cell carcinoma. (Abstract)

as a predictor of occult lymph-node metastasis in OSCC. Eighty-seven patients with primary OSCC arising in the tongue or floor of mouth, clinically T1N0M0 or T2N0M0, with (pN+) and without (pN0) occult lymph-node metastases were analyzed for VEGF-C expression by malignant cells. Occult lymph-node metastases (pN+) were detected in 22% of the 64 patients who were submitted to elective neck dissection. No statistically significant difference was found between OSCC with and without occult lymph-node metastasis (...) Expression of vascular endothelial growth factor-C does not predict occult lymph-node metastasis in early oral squamous cell carcinoma. Strong vascular endothelial growth factor-C (VEGF-C) expression has been correlated to occurrence of lymph-node metastases in patients with oral squamous cell carcinoma (OSCC). The incidence of occult lymph-node metastasis remains a decisive factor in the prognosis of patients with early OSCC. The aim of this study was to evaluate VEGF-C expression

2008 International Journal of Oral and Maxillofacial Surgery

4020. Clinical significance of cellular distribution of moesin in patients with oral squamous cell carcinoma. (Abstract)

specimens from patients with primary OSCC, including 30 patients with locoregional lymph node metastasis, and in the sections from nude mice transplanted with two cell lines derived from a single human tongue cancer (SQUU-A and SQUU-B).Expression patterns of moesin in OSCCs were divided into three groups: membranous pattern; mixed pattern; and cytoplasmic pattern. These expression patterns correlated with tumor size, lymph node metastasis, mode of invasion, differentiation, and lymphocytic infiltration (...) Clinical significance of cellular distribution of moesin in patients with oral squamous cell carcinoma. Moesin is a linking protein of the submembraneous cytoskeleton and plays a key role in the control of cell morphology, adhesion, and motility. The aim of the present study was to elucidate the clinical significance of expression patterns of moesin in patients with oral squamous cell carcinoma (OSCC).Immunohistochemistry for moesin monoclonal antibody was performed on 103 paraffin-embedded

2004 Clinical Cancer Research

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>